Tags: SOCMA Member News


Ascensus Specialties Acquires Strem Chemicals

Wind Point Partners (“Wind Point”) and Ascensus Specialties LLC (“Ascensus”) today announced that Ascensus has completed the acquisition of Strem Chemicals, Inc. (“Strem” or the “Company”). Strem is a global leader in high-purity, research-grade catalysts, ligands, organometallics, metal carbonyls and CVD/ALD precursors.

April 7, 2021





Lonza Reports Strong 2020 Performance, Driven By Sales Growth in Pharma and Biotech Business

Lonza (with the Specialty Ingredients segment – LSI – reported as discontinued operations) today reported strong sales of CHF 4.5 billion, sales growth of 12.0%5, and CHF 1.4 billion CORE EBITDA, resulting in a margin of 31.2%. The results mainly reflect the Pharma Biotech & Nutrition segment (LPBN), which delivered 12.2%5 sales growth and a CORE EBITDA margin of 32.1%.

January 27, 2021



Capricor Collaborates with Lonza for the Development of CAP-1002, its Cell Therapy Candidate for the Treatment of Duchenne Muscular Dystrophy and Other Indications

Capricor Therapeutics, a clinical-stage biotechnology company focused on the development of the first-in-class cell and exosome-based therapeutics for the treatment and prevention of serious diseases, and Lonza today announced that the companies have entered into an agreement for the development of CAP-1002, Capricor's leading clinical asset using allogeneic cardiosphere-derived cells (CDC) technology for the treatment of Duchenne Muscular Dystrophy (DMD) and complications arising from COVID-19.

January 12, 2021